Medivir
11
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
18.2%
2 terminated/withdrawn out of 11 trials
81.8%
-4.7% vs industry average
27%
3 trials in Phase 3/4
56%
5 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
Role: lead
Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer
Role: collaborator
Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)
Role: collaborator
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
Role: lead
A Study to Evaluate the Efficacy, Safety and Tolerability of MIV-711 in Osteoarthritis Patients
Role: lead
A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients
Role: lead
A Bioavailability Study of MIV-711 Oral Formulations in Healthy Volunteers
Role: lead
Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis
Role: lead
Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents
Role: lead
Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients
Role: lead
Efficacy of Acyclovir in Combination With a Glucocorticosteroid on UV-Induced Herpes Labialis
Role: lead
All 11 trials loaded